Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2026 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium in sepsis

Matisse obtains FDA Fast Track Designation for isupartob sodium in sepsis. FDA's Fast Track is designed to get important new drugs to the patient earlier.
May 19, 2026 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium

Matisse Pharmaceuticals announces U.S. FDA clearance of the company’s Investigational New Drug (IND) application for isupartob sodium
December 11, 2025 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229

Matisse Pharmaceuticals receives INN (International Non-proprietary Name) isupartob sodium from the WHO recognizing first-in-class drug status for M6229.
November 13, 2025 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers

Successful phase 1 with prolonged infusion duration could offer an effective solution for irreversibly stopping harmful inflammatory responses in sepsis.